GARS antibody (AA 43-289)

Catalog No. ABIN7596061

The Mouse Monoclonal anti-GARS antibody is suitable to detect GARS in samples from Human. It has been validated for WB, IF, ELISA and ICC.

Quick Overview for GARS antibody (AA 43-289) (ABIN7596061)

Target: GARS (Glycyl-tRNA Synthetase (GARS))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GARS antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF), ELISA, Immunocytochemistry (ICC)

Clone: AT4E10

Product Details anti-GARS Antibody

Binding Specificity: AA 43-289

Purpose: Human GARS antibody

Purification: Purified

Immunogen: Recombinant human GARS (43-289aa) purified from E. coli

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: Phosphate-Buffered Saline ( pH 7.4) with 0.02 % Sodium Azide, 10 % glycerol

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing cycles

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Target Details for GARS

Target: GARS (Glycyl-tRNA Synthetase (GARS))

Alternative Name: GARS

Background: GARS, also known as glycyl-tRNA synthetase, is one of the aminoacyl-tRNA synthetase that charge tRNAswith their cognate amino acids. Defects in the gene encoding GlyRS is the cause of Charcot-Marie-Toothdisease type 2D (CMT2D), which is an autosomal dominant inherited disease characterized by severe weakness,atrophy and absence of deep tendon reflexes in the upper extremities. Defects in the GlyRS gene is also thecause of distal hereditary muscular neuropathy type V (HMN5), a disease similar to CMT2D, though the distalsensory involvement is less severe in HMN5 patients.

NCBI Accession: NP_002038

Pathways: Ribonucleoside Biosynthetic Process